Adenoma Detection RateNCT04102631
A Multicenter Study Evaluating the Effectiveness of Endo.Angel in Improving the Quality of Colonoscopy
A study testing colonoscopy with assistance of Endo.Angel and colonoscopy without assistance of Endo.Angel in people with Adenoma Detection Rate, run by Renmin Hospital of Wuhan University at 1 site in China.
Trial summary
Colonoscopy is a key technique in the detection and diagnosis of lower gastrointestinal diseases. High quality endoscopy results in better disease outcomes. However, the operant level of different endoscopists is significantly different.This study aims to construct a real-time quality monitoring system based on… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Adenoma Detection Rate
- What is being tested?
- colonoscopy with assistance of Endo.Angel and colonoscopy without assistance of Endo.Angel
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,076 participants
- Where
- 1 siteChina
- Study dates
- 30 Aug 2019to 31 Dec 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male or female aged 18 years or above;
- Colonoscopy is needed to further characterize gastrointestinal diseases;
- Ability to read, understand and sign informed consent forms;
- The researchers believe that the subjects can understand the process of the clinical study and are willing and able to complete all the study procedures and follow-up visits to cooperate with the study procedures.
Who cannot join
- Participated in other clinical trials, signed informed consent forms and followed up in other clinical trials.
- Participate in a drug clinical trial and during the elution period of the trial or control drug
- Drug or alcohol abuse or mental disorder in the last 5 years;
- Pregnant or lactating women;
- Patients with multiple polyp syndrome;
- Patients with known space-occupying tumor or intestinal stenosis;
Show all 10Show fewer
- Patients with known perforation or colonic obstruction;
- A history of anaphylaxis with antispasmodic has been documented;
- The researchers did not consider the subjects suitable for colonoscopy;
- The researchers determined that the subjects had high-risk diseases or other special conditions that were not appropriate for clinical trials.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Renmin Hospital of Wuhan University
Wuhan, Hubei, 430060
Honggang Yu, MD, +8613871281899, yuhonggang1968@163.com
About this study
Official title: A Prospective, Randomized, Single-blind, Parallel-controlled Multicenter Study Evaluating the Effectiveness of Endo.Angel in Improving the Quality of Colonoscopy
Colonoscopy is a key technique in the detection and diagnosis of lower gastrointestinal diseases. High quality endoscopy results in better disease outcomes. However, the operant level of different endoscopists is significantly different.This study aims to construct a real-time quality monitoring system based on computer vision, named Endo.Angel, which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
Read the detailed description
This study aims to construct a real-time quality monitoring system based on computer vision, named Endo.Angel, which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.Criteria for inclusion and exclusion are determined prior to endoscopic examination. Candidates who meet all inclusion criteria as well as do not meet all exclusion criteria are bring into the study. Participants randomized before the examination, they are divided into the exposed group assisted by Endo.Angel or the non-exposed group without Endo.Angel. Followup are conducted after the examination.Study will be finished when all followup is done,and the examination result collected from participants will send to an independent review data analysis group.
- Conditions
- Adenoma Detection Rate
- Being tested
- colonoscopy with assistance of Endo.Angel, colonoscopy without assistance of Endo.Angel
- Keywords
- colonoscopy, computer vision, adenoma detection rate, Endo.Angel
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
colonoscopy with assistance of Endo.AngelDiagnostic test
Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
colonoscopy without assistance of Endo.AngelDiagnostic test
Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
| Study group | Role | What they receive |
|---|---|---|
| exposed group | Experimental | patients will receive colonoscopy with assistance of Endo.Angel Receives: Diagnostic Test: colonoscopy with assistance of Endo.Angel |
| non-exposed group | Sham comparator | patients will receive colonoscopy without assistance of Endo.Angel Receives: Diagnostic Test: colonoscopy without assistance of Endo.Angel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Adenoma detection rate
The numerator is the number of cases of adenoma detected by colonoscopy, and the denominator is the total number of cases of patients undergoing colonoscopy.
Measured: 3 months
Secondary outcomes (12)
The mean number of polyps per procedure
The numerator is the total number of polyps detected by colonoscopy, and the denominator is the total number of patients undergoing colonoscopy.
Measured: 3 months
Polyp Detection Rate
The numerator is the number of patients with polyps detected by colonoscopy, and the denominator is the total number of patients receiving colonoscopy.
Measured: 3 months
The mean number of adenomas per procedure
The numerator is the total number of adenomas detected by colonoscopy, and the denominator is the total number of patients undergoing colonoscopy.
Measured: 3 months
Detection rate of large, small and minimal polyps
The numerator was the number of patients with large (≥10 mm), small (4-9 mm), and minimal(≤5 mm) polyps detected by colonoscopy, and the denominator was the total number of patients receiving colonoscopy
Measured: 3 months
The mean number of large, small and minimal polyps per procedure
The numerator was the number of large (≥10 mm), small (4-9 mm), and minimal (≤5 mm) polyps detected by colonoscopy, and the denominator was the total number of patients receiving colonoscopy.
Measured: 3 months
Detection rate of large, small and minimal adenomas
The numerator was the number of patients with large (≥10 mm), small (4-9 mm), and minimal(≤5 mm) adenomas detected by colonoscopy, and the denominator was the total number of patients receiving colonoscopy
Measured: 3 months
The mean number of large, small and minimal adenomas per procedure
The numerator was the number of large (≥10 mm), small (4-9 mm), and minimal (≤5 mm) adenomas detected by colonoscopy, and the denominator was the total number of patients receiving colonoscopy.
Measured: 3 months
Detection rate of adenoma in different sites
The numerator is the number of cases of adenoma detected in the rectum, sigmoid colon, descending colon, transverse colon, ascending colon and ileocecal region during colonoscopy, and the denominator is the total number of patients undergoing colonoscopy.
Measured: 3 months
The mean number of adenomas in different sites per procedure
The numerator is the total number of adenomas detected in the rectum, sigmoid colon, descending colon, transverse colon, ascending colon and ileocecal region during colonoscopy, and the denominator is the total number of patients undergoing colonoscopy.
Measured: 3 months
Time of colonoscopic withdrawal
the duration of colonoscopic withdrawal(not include the time of biopsy or treatment).
Measured: 3 months
Time of colonoscopic insertion
The time of colonoscopy from the rectum to the ileocecal area.
Measured: 3 months
The rate of reaching the ileocecal region
The numerator is the number of cases of colonic examination reaching the ileocecal region, and the denominator is the total number of colonoscopy cases.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2019
- Study start30 Aug 2019
- Primary completion30 Nov 2019 (estimated)
- Study completion31 Dec 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adenoma Detection RateStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 1,076 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Renmin Hospital of Wuhan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yu Honggang, Renmin Hospital of Wuhan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04102631
- Sponsor's protocol ID
- EA-18-002
- Status last verified
- Sep 2019
- First submitted
- 23 Sep 2019
- Last updated
- 25 Sep 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Randomized, Single-blind, Parallel-controlled Multicenter Study Evaluating the Effectiveness of Endo.Angel in Improving the Quality of Colonoscopy
- ClinicalTrials.gov ID
- NCT04102631
- Acronym / sponsor ID
- EA-18-002
- Conditions
- Adenoma Detection Rate
- Keywords
- colonoscopy, computer vision, adenoma detection rate, Endo.Angel
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 1,076 participants (estimated)
- Lead sponsor
- Renmin Hospital of Wuhan UniversityUniversity, hospital or other
- Study start
- 30 Aug 2019 (actual)
- Primary completion
- 30 Nov 2019 (estimated)
- Study completion
- 31 Dec 2019 (estimated)
- First posted
- 25 Sep 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Colonoscopy is a key technique in the detection and diagnosis of lower gastrointestinal diseases. High quality endoscopy results in better disease outcomes. However, the operant level of different endoscopists is significantly different.This study aims to construct a real-time quality monitoring system based on computer vision, named Endo.Angel, which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
Detailed description
This study aims to construct a real-time quality monitoring system based on computer vision, named Endo.Angel, which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.Criteria for inclusion and exclusion are determined prior to endoscopic examination. Candidates who meet all inclusion criteria as well as do not meet all exclusion criteria are bring into the study. Participants randomized before the examination, they are divided into the exposed group assisted by Endo.Angel or the non-exposed group without Endo.Angel. Followup are conducted after the examination.Study will be finished when all followup is done,and the examination result collected from participants will send to an independent review data analysis group.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| exposed group | Experimental | Diagnostic Test: colonoscopy with assistance of Endo.Angelpatients will receive colonoscopy with assistance of Endo.Angel |
| non-exposed group | Sham comparator | Diagnostic Test: colonoscopy without assistance of Endo.Angelpatients will receive colonoscopy without assistance of Endo.Angel |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Male or female aged 18 years or above;
- Colonoscopy is needed to further characterize gastrointestinal diseases;
- Ability to read, understand and sign informed consent forms;
- The researchers believe that the subjects can understand the process of the clinical study and are willing and able to complete all the study procedures and follow-up visits to cooperate with the study procedures.
Key exclusion criteria (10 listed)
- Participated in other clinical trials, signed informed consent forms and followed up in other clinical trials.
- Participate in a drug clinical trial and during the elution period of the trial or control drug
- Drug or alcohol abuse or mental disorder in the last 5 years;
- Pregnant or lactating women;
- Patients with multiple polyp syndrome;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| colonoscopy with assistance of Endo.AngelPatients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping. | Diagnostic test | exposed group |
| colonoscopy without assistance of Endo.AngelPatients in non-exposed group will receive colonoscopy without assistance of Endo.Angel. | Diagnostic test | non-exposed group |
Primary outcome
Adenoma detection rate
Time frame: 3 months
The numerator is the number of cases of adenoma detected by colonoscopy, and the denominator is the total number of cases of patients undergoing colonoscopy.
12 secondary outcomes
The mean number of polyps per procedure
Time frame: 3 months
Polyp Detection Rate
Time frame: 3 months
The mean number of adenomas per procedure
Time frame: 3 months
Detection rate of large, small and minimal polyps
Time frame: 3 months
The mean number of large, small and minimal polyps per procedure
Time frame: 3 months
Detection rate of large, small and minimal adenomas
Time frame: 3 months
The mean number of large, small and minimal adenomas per procedure
Time frame: 3 months
Detection rate of adenoma in different sites
Time frame: 3 months
The mean number of adenomas in different sites per procedure
Time frame: 3 months
Time of colonoscopic withdrawal
Time frame: 3 months
Time of colonoscopic insertion
Time frame: 3 months
The rate of reaching the ileocecal region
Time frame: 3 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2019.
Related trials for Adenoma Detection Rate
Recruiting
Comparison of the Performance Between Conventional Colonoscopy and 3D Colonoscopy in Positive Fecal Immunochemical Test Group
Adenoma Detection Rate, Colonoscopy
Recruiting
Comparison of Adenoma Detection Rate in 3D vs. 2D Surveillance Colonoscopy
Colonoscopy, Adenoma Detection Rate
Not yet recruiting
Right Colon Enema to Improve Bowel Preparation Quality During Colonoscopy
Colonic Polyps, Colorectal Neoplasms
Recruiting
Artificial Intelligence (AI) Assisted Real-time Adenoma Detection and Classification During Colonoscopies
Artificial Intelligence
Not yet recruiting
Effectiveness of Artificial Intelligence-Assisted Colonoscopy for Adenoma Detection in Routine Clinical Practice : a Prospective Multicenter Randomized Trial
Colorectal Neoplasms, Colonic Polyp
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing colonoscopy with assistance of Endo.Angel and colonoscopy without assistance of Endo.Angel in people with Adenoma Detection Rate, run by Renmin Hospital of Wuhan University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Honggang Yu, MD (+8613871281899, yuhonggang1968@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adenoma detection rate (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2019.